A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray
Phase 4
Withdrawn
- Conditions
- Allergic Rhinitis
- Interventions
- Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide
- Registration Number
- NCT00793858
- Lead Sponsor
- University of Chicago
- Brief Summary
The purpose of this study is to measure the amount of a nasal steroid spray (ciclesonide) absorbed by the tissue in the nose 2 hours after having this study drug sprayed in the nose
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Males and females 18 years of age or older.
- History of perennial allergic rhinitis for at least 1 year prior to screening.
- Positive skin test to perennial allergen.
Exclusion Criteria
- Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
- Pregnant or lactating women.
- Upper respiratory infection within 14 days of study start.
- Active asthma requiring treatment with inhaled or systemic steroids.
- Use of any form of nasal spray during the previous month.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 4 placebo, isotonic ciclesonide, hypotonic ciclesonide isotonic ciclesonide in both right and left nostrils 1 placebo, isotonic ciclesonide, hypotonic ciclesonide placebo in left nostril, isotonic ciclesonide in right 2 placebo, isotonic ciclesonide, hypotonic ciclesonide hypotonic ciclesonide in left nostril, placebo in right 3 placebo, isotonic ciclesonide, hypotonic ciclesonide hypotonic ciclesonide in right and left nostrils 6 placebo, isotonic ciclesonide, hypotonic ciclesonide placebo in both right and left nostrils 5 placebo, isotonic ciclesonide, hypotonic ciclesonide isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
- Primary Outcome Measures
Name Time Method levels of ciclesonide in biopsy tissue 2 hours post study drug administration
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States